2014
Carcinoma-associated retinopathy in a young teenager with immature teratoma of the ovary
Turaka K, Kietz D, Krishnamurti L, Mitchell E, Scanga H, Fu V, Sylvester C. Carcinoma-associated retinopathy in a young teenager with immature teratoma of the ovary. Journal Of American Association For Pediatric Ophthalmology And Strabismus 2014, 18: 396-398. PMID: 25173906, DOI: 10.1016/j.jaapos.2014.03.007.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAntibodies, Monoclonal, Murine-DerivedAntineoplastic AgentsArrestinAutoantibodiesAutoantigensColor Vision DefectsDrug Therapy, CombinationElectroretinographyEvoked Potentials, VisualFemaleFluorescein AngiographyGlucocorticoidsHumansImmunoglobulins, IntravenousImmunologic FactorsMethylprednisoloneOvarian NeoplasmsOvariectomyParaneoplastic Syndromes, OcularPrednisoloneRituximabTeratomaTomography, Optical CoherenceVisual AcuityConceptsIntravenous immunoglobulinVisual acuityRetinal pigment epithelial atrophyCarcinoma-associated retinopathyPigment epithelial atrophyPulse intravenous methylprednisoloneRight ovarian massEye 1 weekSlit-lamp biomicroscopyAntiretinal autoantibodiesColor visionIntravenous methylprednisoloneSystemic prednisoloneEpithelial atrophyFundus examinationImmature teratomaLeft eyeVEP findingsOvarian massesPeripheral retinaRight eyeDiminished visionPatchy areasPotential testingCone responses
2009
Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS)
Rao V, Price S, Perkins K, Aldridge P, Tretler J, Davis J, Dale J, Gill F, Hartman K, Stork L, Gnarra D, Krishnamurti L, Newburger P, Puck J, Fleisher T. Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS). Pediatric Blood & Cancer 2009, 52: 847-852. PMID: 19214977, PMCID: PMC2774763, DOI: 10.1002/pbc.21965.Peer-Reviewed Original ResearchConceptsAutoimmune lymphoproliferative syndromeAutoimmune hemolytic anemiaRefractory immune thrombocytopeniaMedian response durationUse of rituximabDisorder of apoptosisMarked lymphadenopathyProlonged neutropeniaRituximab infusionRituximab useSurgical splenectomyALPS patientsImmune thrombocytopeniaPalpable spleenRituximab therapySignificant splenomegalyPolysaccharide vaccineAutoimmune destructionMedication optionsMultilineage cytopeniasRefractory cytopeniaAutoreactive lymphocytesAsplenic individualsAntibody responseLymphoproliferative syndrome